In this edition:
– Ferric carboxymaltose in HF with iron deficiency
– Semaglutide in HFPEF and obesity
– Clinical characteristics and HF outcomes: LVEF thresholds and inflection points
– Obesity in HFPEF with or without diabetes
– VAI and HF risk, late-life cardiac structure and function
– Blinded withdrawal of long-term empagliflozin or placebo in HF
– Cardiac and metabolic effects of dapagliflozin in HFPEF
– Age, sex and outcomes in HFREF
– 5-year mortality in patients managed with magnetically levitated LVAD
– MRA underutilisation in HFREF